Financial Performance Summary (Consolidated)

Revenue Performance:

  • Revenue from Operations: ₹6,951 million in Q1 FY27 vs ₹6,132 million in Q1 FY26 (13% YoY growth)
  • Quarterly comparison: ₹6,951 million in Q1 FY27 vs ₹6,523 million in Q4 FY26 (7% QoQ growth)

Profitability Metrics:

  • Adjusted EBITDA: ₹1,339 million in Q1 FY27 vs ₹1,118 million in Q1 FY26 (20% YoY growth)
  • Adjusted EBITDA margin: 19.4% in Q1 FY27 vs 18.2% in Q1 FY26 (121 bps expansion)
  • Quarterly EBITDA comparison: ₹1,339 million in Q1 FY27 vs ₹1,252 million in Q4 FY26 (7% QoQ growth)
  • Adjusted PAT: ₹138 million in Q1 FY27 vs ₹47 million in Q1 FY26 (190% YoY growth)
  • Adjusted PAT margin: 2.0% in Q1 FY27 vs 0.8% in Q1 FY26
  • Quarterly PAT comparison: ₹138 million in Q1 FY27 vs ₹341 million in Q4 FY26 (-59.6% QoQ decline)

Operational Highlights:

  • Volume growth: 11% YoY increase in patient volumes
  • Average Revenue Per Patient (ARPP): 2% YoY growth
  • Non-institutional revenue grew 17% YoY, increasing contribution from 67% to 69%
  • International business revenue: ₹208 million, growing ~9% YoY
  • Fertility Business (divested in June 2026): delivered revenue of ₹169 million and EBITDA of ₹23 million in Q1 FY27
  • North Bangalore hospital (commenced operations in May 2026): contributed ₹67 million in Q1 FY27 with reported loss of ₹70 million

Notes on Financial Adjustments:

  • Adjusted EBITDA excludes ESOP and one-time expenses, and in Q1 FY27 also excludes North Bangalore Loss of ₹70 million
  • Q4 FY26 PAT post non-controlling interest normalized for one-time exceptional item pertaining to goodwill impairment of fertility business

Strategic and Operational Developments

Capacity Expansion:

  • Successfully commissioned state-of-the-art 120+ bed hospital in North Bangalore, Hebbal in May 2026
  • 56 beds operational in first phase at North Bangalore
  • Total 121 operational beds added during the quarter across multiple locations:
  • 56 beds at North Bangalore
  • 26 beds at Ranchi
  • 19 beds at Borivali
  • 8 beds at Nashik
  • 5 beds at Hubli
  • 7 beds at Kenya

Clinical Capability Enhancements:

  • North Bangalore hospital: MR Linac commissioned in July 2026, making it home to one of India's most advanced adaptive radiation therapy platforms
  • Recorded 550+ new patient registrations and 300+ admissions since launch at North Bangalore
  • Rajkot hospital became Comprehensive Cancer Care (CCC) Centre following commissioning of new LINAC
  • Expanded robotic surgery capabilities with addition of two high-end surgical robotic systems:
  • New installation at Nashik
  • Replacement robot installed at Bangalore CoE

Network Performance:

  • 16 of 25 centers recorded their highest-ever quarterly revenues (excluding North Bangalore hospital)
  • Broad-based growth across network with sustained demand for oncology services

Management Commentary

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman:

Emphasized the strong start to FY27 reflecting the resilience of HCG's integrated oncology model and commitment to clinical excellence. Highlighted consistent investments in expanding access to advanced cancer care while building an institution combining cutting-edge technology, world-class medical expertise, and compassionate patient care. Committed to strengthening network through strategic capacity expansion and focused investments in innovation.

Dr. Manish Mattoo, Executive Director & CEO:

Noted strong start to FY27 with 13% YoY revenue growth. Highlighted focus on increasing share of high-complexity oncology care and non-institutional business strengthening revenue quality. Expressed encouragement by strong response to new North Bangalore hospital, expected to contribute meaningfully as insurance empanelment progresses and onboarded doctors ramp up practices. Committed to strengthening clinical leadership, expanding capacity in high-potential markets, and delivering sustainable, profitable growth.

Additional Information

  • Board meeting held on August 06, 2026 approved the unaudited financial results
  • Results filed under Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Information available on company website: https://www.hcgoncology.com/investor-relations/